-
Je něco špatně v tomto záznamu ?
Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate
P. Gibala, M. Douša, A. Kalužíková, M. Tkadlecová, M. Štefko, S. Kalášek, J. Břicháč,
Journal of pharmaceutical and biomedical analysis.
2019 ;
162 (-) :
112-116.
[pub] 20180726
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Perzistentní odkaz
https://www.medvik.cz/link/bmc19012352
- MeSH
- amlodipin chemie MeSH
- časové faktory MeSH
- chromatografie s reverzní fází MeSH
- farmaceutická chemie metody MeSH
- fixní kombinace léků MeSH
- formaldehyd chemie MeSH
- hmotnostní spektrometrie s elektrosprejovou ionizací MeSH
- hydrochlorthiazid chemie MeSH
- kontaminace léku * MeSH
- magnetická rezonanční spektroskopie MeSH
- molekulární struktura MeSH
- pomocné látky chemie MeSH
- stabilita léku MeSH
- valsartan chemie MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- Publikační typ
- časopisecké články MeSH
New unknown impurity at m/z 421.15 was observed during the accelerated stability analysis (40 °C/75% relative humidity) in the multi-component tablets of amlodipine besylate by reversed-phase ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS). UHPLC-MS and nuclear magnetic resonance (NMR) techniques were employed to identify and fully characterize the degradation compound. The degradation product was unambiguously identified as 3-ethyl 5-methyl 4-(2-chlorophenyl)-6-methyl-2-(morpholin-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate and mechanism of its formation was proposed. It was confirmed that the degradation product was formed by the reaction of amlodipine with formaldehyde originating from the excipients present in the dosage form.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012352
- 003
- CZ-PrNML
- 005
- 20190405092755.0
- 007
- ta
- 008
- 190405s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2018.07.040 $2 doi
- 035 __
- $a (PubMed)30236818
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Gibala, Petr $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 245 10
- $a Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate / $c P. Gibala, M. Douša, A. Kalužíková, M. Tkadlecová, M. Štefko, S. Kalášek, J. Břicháč,
- 520 9_
- $a New unknown impurity at m/z 421.15 was observed during the accelerated stability analysis (40 °C/75% relative humidity) in the multi-component tablets of amlodipine besylate by reversed-phase ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS). UHPLC-MS and nuclear magnetic resonance (NMR) techniques were employed to identify and fully characterize the degradation compound. The degradation product was unambiguously identified as 3-ethyl 5-methyl 4-(2-chlorophenyl)-6-methyl-2-(morpholin-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate and mechanism of its formation was proposed. It was confirmed that the degradation product was formed by the reaction of amlodipine with formaldehyde originating from the excipients present in the dosage form.
- 650 _2
- $a amlodipin $x chemie $7 D017311
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a chromatografie s reverzní fází $7 D056148
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 12
- $a kontaminace léku $7 D004340
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a pomocné látky $x chemie $7 D005079
- 650 _2
- $a formaldehyd $x chemie $7 D005557
- 650 _2
- $a hydrochlorthiazid $x chemie $7 D006852
- 650 _2
- $a magnetická rezonanční spektroskopie $7 D009682
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a valsartan $x chemie $7 D000068756
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Douša, Michal $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz.
- 700 1_
- $a Kalužíková, Aneta $u Department of Analytical Chemistry, Faculty of Science, Charles University in Prague, Hlavova 2030/8, CZ-128 43 Prague 2, Czech Republic; The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, CZ-166 10 Prague 6, Czech Republic.
- 700 1_
- $a Tkadlecová, Marcela $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Štefko, Martin $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Kalášek, Stanislav $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Břicháč, Jiří $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 162, č. - (2019), s. 112-116
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30236818 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190405092805 $b ABA008
- 999 __
- $a ok $b bmc $g 1391662 $s 1050657
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 162 $c - $d 112-116 $e 20180726 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20190405
